The U.S. Food and Drug Administration on Thursday approved tebipenem pivoxil hydrobromide (Utebzi) for the treatment of complicated urinary tract infections, including pyelonephritis, in adult patients — marking the first time a carbapenem antibiotic has been made available in an oral formulation anywhere in the world.

The approval, anticipated for today’s PDUFA date, follows a resubmission by Spero Therapeutics and its partner GSK after the agency had previously declined to approve the drug in 2022 over concerns about trial design. The resubmission addressed those concerns with additional data from a non-inferiority study comparing tebipenem HBr against intravenous imipenem-cilastatin in hospitalized adult patients with cUTI.

The pivotal trial met its primary endpoint. Tebipenem HBr demonstrated non-inferiority to IV imipenem-cilastatin on the composite endpoint of symptomatic resolution and microbiological eradication at test-of-cure. The safety profile was consistent with the carbapenem class: the most common adverse events were diarrhea and headache, both mild to moderate in severity.

The clinical significance of this approval is hard to overstate. Carbapenems represent the last line of defence against gram-negative bacteria carrying extended-spectrum beta-lactamase (ESBL) enzymes and other resistance mechanisms. Until now, their use required intravenous administration, meaning patients either needed hospital admission or prolonged outpatient IV infusion. An oral carbapenem changes that calculus for a meaningful subset of patients with drug-resistant cUTI who are otherwise clinically stable.

Antimicrobial resistance remains one of the defining public health challenges of the decade. The World Health Organization has repeatedly identified carbapenem-resistant Enterobacterales as priority pathogens, and the U.S. CDC estimates that drug-resistant infections cause more than 35,000 deaths annually in the United States. Tebipenem’s oral bioavailability — achieved through a pivoxil prodrug that is hydrolysed to the active tebipenem moiety in the intestinal wall — positions it as a potential step-down therapy after initial IV treatment, or as a primary outpatient option in carefully selected patients.

The mechanism of action follows the established carbapenem pathway: inhibition of penicillin-binding proteins PBP-2 and PBP-3, disrupting bacterial cell wall synthesis. Tebipenem demonstrates activity against many ESBL-producing Enterobacterales, though it lacks coverage against carbapenemase-producing organisms, a limitation that clinicians will need to weigh against susceptibility testing.

Regulatory approval in a challenging antibiotic environment also reflects the ongoing policy effort to sustain antibiotic development pipelines that have historically struggled to attract commercial investment. The GAIN Act and PASTEUR Act frameworks have created some financial incentives, but the economics of antibiotics remain structurally difficult. Today’s approval is a data point that the FDA remains committed to facilitating viable pathways for novel antimicrobials.

Utebzi is expected to enter the U.S. market in the coming months, with pricing and reimbursement negotiations ongoing.